---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062001"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:35:19.380973+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Marker Q1 net loss narrows to $2.4M; MT-601 shows durable CRs in APOLLO trial

## Summary
- Net loss of $2.4M in Q1 2024 vs $4.9M in Q1 2023; cash $11.3M expected to fund into Q4 2025.
- Three patients treated with MT-601: 2 complete responses (one >9 months after CAR-T relapse) and 1 partial response; well tolerated.
- MT-601 received nonproprietary name 'neldaleucel' from USAN/INN; more data expected H2 2024.
- MT-401-OTS IND cleared for AML/MDS; clinical initiation expected H2 2024; secured $2M NIH SBIR funding.
- R&D expenses $2.6M, G&A $1.2M, both down YoY.

## SEC filing metadata
- accession: 0001104659-24-062001
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/0001104659-24-062001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/tm2414438d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062001
- JSON: https://secwatch.observer/filing/0001104659-24-062001.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062001.txt

## Key facts
- Earnings Releases
  Marker Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/0001104659-24-062001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.